<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39434078</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Molecular cancer</Title><ISOAbbreviation>Mol Cancer</ISOAbbreviation></Journal><ArticleTitle>MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2.</ArticleTitle><Pagination><StartPage>235</StartPage><MedlinePgn>235</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">235</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12943-024-02094-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer patients are more susceptible to an aggressive course of COVID-19. Developing biomarkers identifying cancer patients at high risk of COVID-19-related death could help determine who needs early clinical intervention. The miRNAs hosted in the genomic regions associated with the risk of aggressive COVID-19 could represent potential biomarkers for clinical outcomes.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Plasma samples were collected at The University of Texas MD Anderson Cancer Center from cancer patients (N = 128) affected by COVID-19. Serum samples were collected from vaccinated healthy individuals (n = 23) at the Municipal Clinical Emergency Teaching Hospital in Timisoara, Romania. An in silico positional cloning approach was used to identify the presence of miRNAs at COVID-19 risk-associated genomic regions: CORSAIRs (COvid-19 RiSk AssocIated genomic Regions). The miRNA levels were measured by RT-qPCR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that miRNAs were enriched in CORSAIR. Low plasma levels of hsa-miR-150-5p and hsa-miR-93-5p were associated with higher COVID-19-related death. The levels of hsa-miR-92b-3p were associated with SARS-CoV-2 test positivity. Peripheral blood mononuclear cells (PBMC) increased secretion of hsa-miR-150-5p, hsa-miR-93-5p, and hsa-miR-92b-3p after in vitro TLR7/8- and T cell receptor (TCR)-mediated activation. Increased levels of these three miRNAs were measured in the serum samples of healthy individuals between one and nine months after the second dose of the Pfizer-BioNTech COVID-19 vaccine. SARS-CoV-2 infection of human airway epithelial cells influenced the miRNA levels inside their secreted extracellular vesicles.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MiRNAs are enriched at CORSAIR. Plasma miRNA levels can represent a potential blood biomarker for predicting COVID-19-related death in cancer patients.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Anfossi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. sanfossi@mdanderson.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Darbaniyan</LastName><ForeName>Faezeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematopoietic Biology &amp; Malignancy, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calin</LastName><ForeName>Steliana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hemopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Masayoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rausseo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winters</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Cell Biology, West Virginia University Cancer Institute, Morgantown, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogatenkova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Kim-Anh</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Cell Biology, West Virginia University Cancer Institute, Morgantown, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ziyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antal</LastName><ForeName>Loredana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Municipal Clinical Emergency Hospital, Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Olariu</LastName><ForeName>Tudor Rares</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Municipal Clinical Emergency Hospital, Timisoara, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Center for Diagnosis and Study of Parasitic Diseases, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wistuba</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Calin</LastName><ForeName>George A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. gcalin@mdanderson.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Non-coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, USA. gcalin@mdanderson.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Cancer</MedlineTA><NlmUniqueID>101147698</NlmUniqueID><ISSNLinking>1476-4598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Genomics</Keyword><Keyword MajorTopicYN="N">MiRNAs</Keyword><Keyword MajorTopicYN="N">Plasma biomarkers</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>7</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434078</ArticleId><ArticleId IdType="pmc">PMC11492698</ArticleId><ArticleId IdType="doi">10.1186/s12943-024-02094-9</ArticleId><ArticleId IdType="pii">10.1186/s12943-024-02094-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal R, Millar T, Lerpiniere CEB, Tagliavini G, Hartley CS, et al. Tissue-Specific Immunopathology in Fatal COVID-19. Am J Respir Crit Care Med. 2021;203:192–201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7874430</ArticleId><ArticleId IdType="pubmed">33217246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan. China JAMA. 2020;323:1061–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, Song Q, Jia Q, Wang J. Clinical characteristics of 82 cases of death from COVID-19. PLoS ONE. 2020;15: e0235458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347130</ArticleId><ArticleId IdType="pubmed">32645044</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JD, Gonzalez MA, Rüthrich MM, Sharon E, von Lilienfeld-Toal M. COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. Am Soc Clin Oncol Educ Book. 2022;42:1–13.</Citation><ArticleIdList><ArticleId IdType="pubmed">35658503</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, Bujanda L, Bouysran Y, Niemi ME, Palom A, et al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest. 2021;131(23):e152386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631592</ArticleId><ArticleId IdType="pubmed">34597274</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591:92–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Severe Covid GG, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernandez J, Prati D, Baselli G, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383:1522–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum Genomics. 2020;14:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578581</ArticleId><ArticleId IdType="pubmed">33092637</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbester JL, Humphreys IR. Genetic influences on viral-induced cytokine responses in the lung. Mucosal Immunol. 2021;14:14–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658619</ArticleId><ArticleId IdType="pubmed">33184476</ArticleId></ArticleIdList></Reference><Reference><Citation>Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365734</ArticleId><ArticleId IdType="pubmed">14973191</ArticleId></ArticleIdList></Reference><Reference><Citation>Giza DE, Fuentes-Mattei E, Bullock MD, Tudor S, Goblirsch MJ, Fabbri M, Lupu F, Yeung SJ, Vasilescu C, Calin GA. Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications. Cell Death Differ. 2016;23:1906–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5136497</ArticleId><ArticleId IdType="pubmed">27740627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16:279–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27121651</ArticleId></ArticleIdList></Reference><Reference><Citation>Virga F, Cappellesso F, Stijlemans B, Henze AT, Trotta R, Van Audenaerde J, Mirchandani AS, Sanchez-Garcia MA, Vandewalle J, Orso F, et al. Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. Sci Adv. 2021;7(19):eabf0466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7616432</ArticleId><ArticleId IdType="pubmed">33962944</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, Bernad A, Sanchez-Madrid F. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011;2:282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104548</ArticleId><ArticleId IdType="pubmed">21505438</ArticleId></ArticleIdList></Reference><Reference><Citation>Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, Seabra MC, Wilson MS. MicroRNA-Containing T-Regulatory-Cell-Derived Exosomes Suppress Pathogenic T Helper 1 Cells. Immunity. 2014;41:503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5640441</ArticleId><ArticleId IdType="pubmed">28903020</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol. 2002;168:3235–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11907077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD, Song E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer. 2011;10:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190352</ArticleId><ArticleId IdType="pubmed">21939504</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, Seabra MC, Round JL, Ward DM, O’Connell RM. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun. 2015;6:7321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557301</ArticleId><ArticleId IdType="pubmed">26084661</ArticleId></ArticleIdList></Reference><Reference><Citation>Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS ONE. 2014;9: e83113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885405</ArticleId><ArticleId IdType="pubmed">24416156</ArticleId></ArticleIdList></Reference><Reference><Citation>Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol. 2018;15:541–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">29784926</ArticleId></ArticleIdList></Reference><Reference><Citation>Olariu TR, Ursoniu S, Marincu I, Lupu MA. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study. Medicina (Kaunas). 2021;57(12):1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8708569</ArticleId><ArticleId IdType="pubmed">34946275</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>EUA Authorized Serology Test Performance. https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.</Citation></Reference><Reference><Citation>Patrick Royston WS. Multivariable Model - Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables. Hoboken: Wiley; 2008.</Citation></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.</Citation></Reference><Reference><Citation>Gray RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat. 1988;16:1141–54.</Citation></Reference><Reference><Citation>Blobel GA, Higgs DR, Mitchell JA, Notani D, Young RA. Testing the super-enhancer concept. Nat Rev Genet. 2021;22:749–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">34480110</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U, Goodstein D, Couronne O, Tran-Gyamfi M, et al. The DNA sequence and biology of human chromosome 19. Nature. 2004;428:529–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057824</ArticleId></ArticleIdList></Reference><Reference><Citation>Flor I, Bullerdiek J. The dark side of a success story: microRNAs of the C19MC cluster in human tumours. J Pathol. 2012;227:270–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22374805</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephen S, Pheasant M, Makunin IV, Mattick JS. Large-scale appearance of ultraconserved elements in tetrapod genomes and slowdown of the molecular clock. Mol Biol Evol. 2008;25:402–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056681</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidinger P, Backes C, Meder B, Meese E, Keller A. The human miRNA repertoire of different blood compounds. BMC Genomics. 2014;15:474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076980</ArticleId><ArticleId IdType="pubmed">24928098</ArticleId></ArticleIdList></Reference><Reference><Citation>Initiative C-HG. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, Ferracin M, Nicoloso MS, Barbarotto E, Popa M, Stanciulea O, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS ONE. 2009;4:e7405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756627</ArticleId><ArticleId IdType="pubmed">19823581</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvan-Pena S, Leon J, Chowdhary K, Michelson DA, Vijaykumar B, Yang L, Magnuson AM, Chen F, Manickas-Hill Z, Piechocka-Trocha A, et al. Profound Treg perturbations correlate with COVID-19 severity. Proc Natl Acad Sci U S A. 2021;118(37):e2111315118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449354</ArticleId><ArticleId IdType="pubmed">34433692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn KM, Lee SG, Kim HJ, Cheon S, Jeong H, Lee J, Kim IS, Silwal P, Kim YJ, Paik S, et al. COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis. J Korean Med Sci. 2020;35: e343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7521960</ArticleId><ArticleId IdType="pubmed">32989935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR, Kutty S. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020;11:1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365905</ArticleId><ArticleId IdType="pubmed">32754159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudor S, Giza DE, Lin HY, Fabris L, Yoshiaki K, D’Abundo L, Toale KM, Shimizu M, Ferracin M, Challagundla KB, et al. Cellular and Kaposi’s sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. Cell Death Dis. 2014;5: e1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649832</ArticleId><ArticleId IdType="pubmed">25476907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, et al. Anti-miR-93–5p therapy prolongs sepsis survival by restoring the peripheral immune response. J Clin Invest. 2023;133(14):e158348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10348769</ArticleId><ArticleId IdType="pubmed">37261908</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Felice G, Visci G, Teglia F, Angelini M, Boffetta P. Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients. Elife. 2022;11:e74634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8956284</ArticleId><ArticleId IdType="pubmed">35171096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Vazquez C, Rodriguez-Galan A, Fernandez-Alfara M, Mittelbrunn M, Sanchez-Cabo F, Martinez-Herrera DJ, Ramirez-Huesca M, Pascual-Montano A, Sanchez-Madrid F. miRNA profiling during antigen-dependent T cell activation: A role for miR-132-3p. Sci Rep. 2017;7:3508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5471249</ArticleId><ArticleId IdType="pubmed">28615644</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Galan A, Dosil SG, Gomez MJ, Fernandez-Delgado I, Fernandez-Messina L, Sanchez-Cabo F, Sanchez-Madrid F. MiRNA post-transcriptional modification dynamics in T cell activation. iScience. 2021;24:102530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8188497</ArticleId><ArticleId IdType="pubmed">34142042</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlgren J, Karlson Tde L, Glader P, Telemo E, Valadi H. Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS ONE. 2012;7: e49723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500321</ArticleId><ArticleId IdType="pubmed">23166755</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 2020;48:D148–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145596</ArticleId><ArticleId IdType="pubmed">31647101</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho RC, Alabed S, Zhou H, Chang SL. Network Meta-analysis on the Changes of Amyloid Precursor Protein Expression Following SARS-CoV-2 Infection. J Neuroimmune Pharmacol. 2021;16:756–69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579188</ArticleId><ArticleId IdType="pubmed">34757528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziff OJ, Ashton NJ, Mehta PR, Brown R, Athauda D, Heaney J, Heslegrave AJ, Benedet AL, Blennow K, Checkley AM, et al. Amyloid processing in COVID-19 associated neurological syndromes. J Neurochem. 2022;161(2):146–57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115071</ArticleId><ArticleId IdType="pubmed">35137414</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier EZ, Buck MD, Chakravarty P, Carvalho J, Frederico B, Cardoso A, Healy L, Ulferts R, Beale R. Reis e Sousa C: An isoform of Dicer protects mammalian stem cells against multiple RNA viruses. Science. 2021;373:231–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611482</ArticleId><ArticleId IdType="pubmed">34244417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S, Hoskins I, Tonn T, Garcia PD, Ozadam H, Sarinay Cenik E, Cenik C. Genes with 5’ terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 Nsp1 protein. RNA. 2021;27:1025–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8370740</ArticleId><ArticleId IdType="pubmed">34127534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Lee YS, Choi Y, Son A, Park Y, Lee KM, Kim J, Kim JS, Kim VN. The SARS-CoV-2 RNA interactome. Mol Cell. 2021;81(2838–2850): e2836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075806</ArticleId><ArticleId IdType="pubmed">33989516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjabi S, Oh SA, Li MO. Regulation of the Immune Response by TGF-beta: From Conception to Autoimmunity and Infection. Cold Spring Harb Perspect Biol. 2017;9(6):a022236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5453394</ArticleId><ArticleId IdType="pubmed">28108486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002;2:46–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11905837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18161752</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gonzalo-Calvo D, Benitez ID, Pinilla L, Carratala A, Moncusi-Moix A, Gort-Paniello C, Molinero M, Gonzalez J, Torres G, Bernal M, et al. Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. Transl Res. 2021;236:147–59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149473</ArticleId><ArticleId IdType="pubmed">34048985</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita Y, Yoshida T, Takagi Y, Tsukamoto H, Takashima K, Kouwaki T, Makino K, Fukushima S, Nakamura K, Oshiumi H. Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination. NPJ Vaccines. 2022;7:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826357</ArticleId><ArticleId IdType="pubmed">35136071</ArticleId></ArticleIdList></Reference><Reference><Citation>Akula SM, Bolin P, Cook PP. Cellular miR-150-5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulating nsp10 gene. RNA Biol. 2022;19:1–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786335</ArticleId><ArticleId IdType="pubmed">34904915</ArticleId></ArticleIdList></Reference><Reference><Citation>Vithani N, Ward MD, Zimmerman MI, Novak B, Borowsky JH, Singh S, Bowman GR. SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential. Biophys J. 2021;120:2880–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007187</ArticleId><ArticleId IdType="pubmed">33794150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, Imbert I, Canard B, Guillemot JC, Lecine P, et al. Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J Biol Chem. 2014;289:25783–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4162180</ArticleId><ArticleId IdType="pubmed">25074927</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouse BT, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10:514–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899649</ArticleId><ArticleId IdType="pubmed">20577268</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Raftogiannis M. The immune response to severe bacterial infections: consequences for therapy. Expert Rev Anti Infect Ther. 2012;10:369–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22397569</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, et al. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatol. 2024;6:e339–51.</Citation><ArticleIdList><ArticleId IdType="pubmed">38734019</ArticleId></ArticleIdList></Reference><Reference><Citation>Spellberg B, Edwards JE Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis. 2001;32:76–102.</Citation><ArticleIdList><ArticleId IdType="pubmed">11118387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, Larner AC, Finbloom DS. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood. 1999;93:1456–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029571</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi K. Unique Action of Interleukin-18 on T Cells and Other Immune Cells. Front Immunol. 2018;9:763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920033</ArticleId><ArticleId IdType="pubmed">29731751</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, McGregor M, Ma T, George AF, Kosters A, et al. SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Cell Rep Med. 2020;1: 100081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437502</ArticleId><ArticleId IdType="pubmed">32839763</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Etayo FJ, Suarez-Fernandez P, Cabrera-Marante O, Arroyo D, Garcinuno S, Naranjo L, Pleguezuelo DE, Allende LM, Mancebo E, Lalueza A, et al. T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. Front Cell Infect Microbiol. 2021;11: 624483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7952877</ArticleId><ArticleId IdType="pubmed">33718270</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncati L, Nasillo V, Lusenti B, Riva G. Signals of T(h)2 immune response from COVID-19 patients requiring intensive care. Ann Hematol. 2020;99:1419–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205481</ArticleId><ArticleId IdType="pubmed">32382776</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9:1123–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, Xu B, Dai Y, Li X, Zhang C, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 2020;5(13):e139834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutinho LL, Oliveira CN, Albuquerque PL, Mota SM, Meneses GC, Martins AM, Junior GB, Clementino MA, Gondim RN, Havt A, et al. Elevated IL-18 predicts poor prognosis in critically ill COVID-19 patients at a Brazilian hospital in 2020–21. Future Microbiol. 2022;17:1287–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9488117</ArticleId><ArticleId IdType="pubmed">36111789</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser SMT, Rana AA, Doffinger R, Kafizas A, Khan TA, Nasser S. Elevated free interleukin-18 associated with severity and mortality in prospective cohort study of 206 hospitalised COVID-19 patients. Intensive Care Med Exp. 2023;11:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9949911</ArticleId><ArticleId IdType="pubmed">36823262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjan LH, Furukawa K, Nagano T, Kiriu T, Nishimura M, Arii J, Hino Y, Iwata S, Nishimura Y, Mori Y. Early Differences in Cytokine Production by Severity of Coronavirus Disease 2019. J Infect Dis. 2021;223:1145–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928883</ArticleId><ArticleId IdType="pubmed">33411935</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang S, Bao C, Yang Z, Liu S, Sun Y, Cao W, Wang T, Schwantes-An TH, Choy JS, Naidu S, et al. SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy. Signal Transduct Target Ther. 2023;8:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998025</ArticleId><ArticleId IdType="pubmed">36894537</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211650</ArticleId><ArticleId IdType="pubmed">32446778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson M, Nicolas B, Ciudad M, Greigert H, Guilhem A, Cladiere C, Straub C, Blot M, Piroth L, Rogier T, et al. T-cell immune response predicts the risk of critical SARS-Cov2 infection in hospitalized COVID-19 patients. Eur J Intern Med. 2022;102:104–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9163020</ArticleId><ArticleId IdType="pubmed">35690570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourgholaminejad A, Pahlavanneshan S, Basiri M. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges. Scand J Immunol. 2022;95: e13131.</Citation><ArticleIdList><ArticleId IdType="pubmed">34936112</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Gozzi L, Iannone A, Lo Tartaro D, Mattioli M, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020;11:3434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338513</ArticleId><ArticleId IdType="pubmed">32632085</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156211</ArticleId><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D, Tian J, Wu X, Li M, Tang X, Rui K, Guo H, Ma J, Xu H, Wang S. G-MDSC-derived exosomes attenuate collagen-induced arthritis by impairing Th1 and Th17 cell responses. Biochim Biophys Acta Mol Basis Dis. 2019;1865: 165540.</Citation><ArticleIdList><ArticleId IdType="pubmed">31470074</ArticleId></ArticleIdList></Reference><Reference><Citation>Honardoost MA, Naghavian R, Ahmadinejad F, Hosseini A, Ghaedi K. Integrative computational mRNA-miRNA interaction analyses of the autoimmune-deregulated miRNAs and well-known Th17 differentiation regulators: An attempt to discover new potential miRNAs involved in Th17 differentiation. Gene. 2015;572:153–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">26307197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med. 2009;206:313–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646583</ArticleId><ArticleId IdType="pubmed">19204109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Heo J, Kang H. miR-92b-3p-TSC1 axis is critical for mTOR signaling-mediated vascular smooth muscle cell proliferation induced by hypoxia. Cell Death Differ. 2019;26:1782–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748132</ArticleId><ArticleId IdType="pubmed">30518907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel S, La Grutta S, Cilluffo G, Perconti G, Bongiovanni A, Giallongo A, Behrends J, Kruppa J, Hermann S, Chiang D, et al. Human airway epithelial extracellular vesicle miRNA signature is altered upon asthma development. Allergy. 2020;75:346–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">31386204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>